Recombinant 2019nCoV antigen-coronavirus papain-like proteinase (PLpro, Nsp3, His Tag)
Data Post DownloadCat No.: GMP-V-2019nCoV-PLpro001
Order information
Package | Catalog No. | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
1mg | GMP-V-2019nCoV-PLpro001-1mg |
5990 | ||
10mg | GMP-V-2019nCoV-PLpro001-10mg |
38790 | ||
100mg | GMP-V-2019nCoV-PLpro001-100mg |
258000 | ||
≥100mg | GMP-V-2019nCoV-PLpro001-xmg |
Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Accession Number | QHD43415.1 |
Expression platform | 2019-nCoV(SARS-CoV-2, SARS2-coronavirus) |
Isotypes | E.coli |
Tag | N-His |
Products description |
Recombinant 2019-nCoV(SARS-CoV-2, SARS2-coronavirus) papain-like Proteinase (PLpro, PL Proteinase,Nsp3) was expressed in E.coli-based prokaryotic cell expression system and the target gene encoding Glu1564-IIe1877 was expressed with 6 HIS tag at the N-terminus. |
Bioactivity validation | In Testing |
Purity | Purity: ≥95% (SDS-PAGE) |
application | Immunogen in Elisa,lateral-flow tests,and other immunoassays;Standard substance The antigen can also be used in drug discovery including antibody screening and lead compound candidates assay. |
predicted Molecular Mass | 38.6kD |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
2019nCoV (SARS-CoV-2) Papain-Like Proteinase (PLpro)
About Coronavirus Papain-Like Proteinase (PLpro)
COVID-19 pandemic is caused by 2019nCoV (SARS-CoV-2) infection. 2019nCoV contains 16 Non-structure protein (Nsp1-Nsp16) that may be drugable targets for antiviral compounds discovery against COVID-191.
2019nCoV (SARS-CoV-2) Papain-Like Proteinase(PLpro) is included in Nsp3. The coronavirus Papain-Like Proteinase(PLpro) has been found as a nucleic acid-binding domain (NAB) with a nucleic acid chaperon function, which is conserved in coronavirus,and one uncharacterized domain termed the marker domain (G2M). Following the G2M are two predicted double-pass transmembrane domains (TM1–2 and TM3–4), a putative metal binding region (ZN) and the Y domain of unknown function (subdomains Y1–3)1,2.
About Nsp3
Nsp3: Nsp3 (200 kDa) is the largest protein encoded by the coronavirus genome (SARS-CoV-2, SARS-CoV, MERS, etc.). Nsp3 is an essential component of the replication and transcription complex. It comprises various domains, the organization of which differs between coronavirus genera, due to duplication or absence of some domains. However, the N-terminal region of the Nsp3 is highly conserved among coronavirus, containing a ubiquitin-like (Ubl) globular fold followed by a flexible, extended acidic-domain (AC domain) rich in glutamic acid (38%). Next to the AC domain is a catalytically active ADP-ribose-1"-phosphatase (ADRP, app-1"-pase) domain (also called macro domain or X domain) thought to play a role during synthesis of viral subgenomic RNAs. SARS Unique Domain (SUD), a domain not yet identified in other coronaviruses from alphacoronavirus and betacoronavirus, follows next. The SUD domain binds oligonucleotides known to form G-quadruplexes. Downstream of the SUD domain is a second Ubl domain and the catalytically active PLpro domain that proteolytically processes the Nsp1/2, Nsp2/3 and Nsp3/4 cleavage sites1,2
High-throughput screening (HTS) assay development of Coronavirus PLpro for antiviral compounds
HTS Approach: Fluorescence resonance energy transfer (FRET) assay for time-dependent kinetic analysis
FRET Substrate: (E-EDANS)RELNGGAPI(K-DABCYL)S (Synthetic)
Simple 2019nCoV (SARS-CoV-2) Papain-Like Proteinase(PLpro) activity assay develoement Protocol2: 2019nCoV (SARS-CoV-2) Papain-Like Proteinase(PLpro) activity assay develoement Protocol article
References
1.
Gordon, D. E. et al. A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. BioRxiv, doi:10.1101/2020.03.22.002386 (2020).
2.
Wojdyla, J. A. et al. Papain-like protease 1 from transmissible gastroenteritis virus: crystal structure and enzymatic activity toward viral and cellular substrates. J Virol 84, 10063-10073, doi:10.1128/JVI.00898-10 (2010).
Recombinant 2019 nCoV (SARS2 coronavirus) Antigens reagents
2019 nCoV (SARS2 coronavirus) Antibodies for COVID-19
Cat No. | Products Name | Expression platform | Isotypes | Bioactivity validation | Order |
GMP-V-2019nCoV-NAb001 |
Anti-2019-nCoV NP human monoclonal antibody | human IgG |
Mammalian (human cell) |
N protein binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with GMP-V-2019nCoV-NAb002 ,GMP-V-2019nCoV-NAb003 ,GMP-V-2019nCoV-NAb004 . |
|
GMP-V-2019nCoV-NAb002 |
Anti-2019-nCoV NP human scFv-Fc antibody |
Scfv | Mammalian (human cell) |
N protein binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with GMP-V-2019nCoV-NAb001 ,GMP-V-2019nCoV-NAb003 ,GMP-V-2019nCoV-NAb004 . |
|
GMP-V-2019nCoV-NAb003 |
Anti-2019-nCoV NP mouse monoclonal antibody (mAb) | Mouse IgG |
Hybridoma | N protein binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with GMP-V-2019nCoV-NAb001 ,GMP-V-2019nCoV-NAb002 ,GMP-V-2019nCoV-NAb004 . |
|
GMP-V-2019nCoV-NAb004 |
Anti-2019-nCoV NP mouse monoclonal antibody (mAb) | Mouse IgG |
Hybridoma | N protein binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with GMP-V-2019nCoV-NAb001 ,GMP-V-2019nCoV-NAb002 ,GMP-V-2019nCoV-NAb003 . |
|
GMP-V-2019nCoV-S1Ab001 |
Anti-2019-nCoV Spike (S1 protein) human monoclonal antibody | human IgG |
Mammalian (human cell) |
S-RBD protein binding, ELISA validated | |
GMP-V-2019nCoV-S1Ab002 |
Anti-2019-nCoV Spike (S1 protein) human monoclonal antibody | human IgG |
Mammalian (human cell) |
S-RBD protein binding, ELISA validated, Western Blot validated |
GeneMedi also provides pre-made the lentivirus, adenovirus and AAV vector for the gene ORF plasmids of 2019 nCoV (SARS2 coronavirus):
https://www.genemedi.net/i/2019-ncov-gene-vectors
Collection of COVID-19 landscape knowledge base
Viral vector-based vaccine; DNA-based vaccine; RNA based vaccine - A landscape for vaccine technology against infectious disease, COVID-19 and tumor.COVID-19 landscape Knowledge Base
An Insight of comparison between COVID-19 (2019-nCoV disease) and SARS in pathology and pathogenesis
Landscape Coronavirus Disease 2019 test (COVID-19 test) in vitro -- A comparison of PCR vs Immunoassay vs Crispr-Based test
- GENEMEDI
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]